New blood tests aim to catch ovarian cancer earlier

NCT ID NCT07693894

Not yet recruiting Diagnosis Sponsor: National and Kapodistrian University of Athens Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study evaluates several experimental blood tests designed to detect ovarian cancer earlier. Researchers compare results from people with ovarian cancer to those without cancer to see how well the tests distinguish between the two. The tests look for specific changes in the blood that may signal cancer. Participation involves providing blood samples, but the results are for research only and not used for diagnosis or medical decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Investigational ovarian cancer biomarker assays (OVA-GLY, OVA-VOC, OVA-miRNA)
What this could lead to: If successful, these blood tests could help detect ovarian cancer earlier, potentially improving treatment options and outcomes.
What could go wrong: These tests are still experimental and not yet proven for routine use. The study is observational, so it will not directly benefit participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.